Bronchopulmonary penetration of isavuconazole in lung transplant recipients-Reference-Cited by-同舟云学术

Bronchopulmonary penetration of isavuconazole in lung transplant recipients

Published:2023-10-18 Issue:10 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Caballero-Bermejo Antonio F.¹²^ORCID,Darnaude-Ximénez Ignacio¹^ORCID,Aguilar-Pérez Myriam³^ORCID,Gomez-Lopez Alicia⁴^ORCID,Sancho-López Aránzazu¹^ORCID,López García-Gallo Cristina³^ORCID,Díaz Nuevo Gema³^ORCID,Diago-Sempere Elena¹^ORCID,Ruiz-Antorán Belén¹^ORCID,Avendaño-Solá Cristina¹^ORCID,Ussetti-Gil Piedad³^ORCID,

Affiliation:

1. Clinical Pharmacology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana , Majadahonda, Madrid, Spain

2. Internal Medicine Department, Mater Misericordiae University Hospital , Dublin, Ireland

3. Respiratory Medicine Department, Lung Transplant Unit, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana , Majadahonda, Madrid, Spain

4. Mycology Reference and Research Laboratory, National Center for Microbiology (CNM), ISCIII , Majadahonda, Madrid, Spain

Abstract

ABSTRACT Isavuconazole’s (ISA) pharmacokinetics was studied among lung transplant recipients to evaluate its bronchopulmonary penetration. This study included 13 patients and showed mean serum concentrations of 3.30 (standard deviation [SD] 0.45), 5.12 (SD 1.36), and 6.31 (SD 0.95) at 2 h, 4 h, and 24 h respectively. Mean concentrations in the epithelial lining fluid were 0.969 (SD 0.895), 2.141 (SD 1.265), and 2.812 (SD 0.693) at the same time points. ISA is a drug with a tolerable safety profile that achieves adequate concentrations in the lung.

Funder

Pfizer

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00613-23

Reference15 articles.

1. Infecciones por mohos en el trasplante pulmonar

2. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

3. Aspergilosis invasora en el receptor de trasplante de órgano sólido

4. Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study)

5. Penetration of Isavuconazole in Ascites Fluid of Critically Ill Patients

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Penetration of isavuconazole into the epithelial lining fluid of patients with pulmonary fungal infections. Comment on: ‘Pharmacokinetics of isavuconazole at different target sites in healthy volunteers after single and multiple intravenous infusions’;Journal of Antimicrobial Chemotherapy;2024-08-06

2. Advances in lung transplantation: 60 years on;Respirology;2024-04-22

3. Successful treatment of Purpureocillium lilacinum pulmonary infection with isavuconazole: A case report;World Journal of Clinical Cases;2024-04-06

4. Pharmacokinetics of isavuconazole at different target sites in healthy volunteers after single and multiple intravenous infusions;Journal of Antimicrobial Chemotherapy;2024-03-28